Clinical Trials

NCT03277105 – A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma

Posted on August 5, 2023 by tsuperadmin -

NCT01559272 – A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Paliperidone Palmitate 3-Month Formulation in Subjects With Schizophrenia

Posted on August 5, 2023 by tsuperadmin -

NCT03464136 – A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to That of Adalimumab in the Treatment of Biologic Naïve Subjects With Moderately-to-Severely Active Crohn’s Disease

Posted on August 5, 2023 by tsuperadmin -

NCT03517722 – A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus

Posted on August 5, 2023 by tsuperadmin -

NCT03896061 – A Videographic Study to Evaluate the Impact of a Pulsed Firing Technique on Staple Line Interventions in Laparoscopic Sleeve Gastrectomy

Posted on August 5, 2023 by tsuperadmin -

NCT02846545 – SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes

Posted on August 5, 2023 by tsuperadmin -

NCT04019041 – A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa

Posted on August 5, 2023 by tsuperadmin -

NCT00668837 – Open Label Extension to R076477-SCH-305 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia

Posted on August 5, 2023 by tsuperadmin -

NCT02951819 – Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma

Posted on August 5, 2023 by tsuperadmin -